Medivir presents data that strengthens the fostrox/Lenvima combination in primary liver cancer at EASL Liver Cancer SummitRead more
MEDIVIR AB – YEAR-END REPORT JANUARY – DECEMBER 2023Read more
Number of shares and votes in Medivir AB on 31 January 2024Read more
Quarterly report presentations
Medivir Corporate Governance documention.
Documentation from Medivir's Annual General Meetings.